A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
This research study is investigating a new medication, mitapivat, for individuals living with alpha or beta thalassemia who rely on frequent blood transfusions. The main goal is to determine if mitapivat can decrease the number of blood transfusions these patients need over time. Participants will receive either mitapivat or a placebo (a dummy drug) to see if the new medicine works and if it's safe. Thalassemia is a blood condition where the body doesn't produce enough healthy red blood cells, often leading to anaemia and requiring transfusions. This study is in its advanced stages, meaning it’s already shown some promise in earlier testing. Researchers want to understand if mitapivat could be a new treatment option to improve the lives of people affected by this condition.
A colpo d'occhio
Risultati
Risultati di questo studio
Pubblicato May 2025I risultati di questo studio sono stati pubblicati.
Di cosa tratta questo studio?
This study is testing a new medicine called mitapivat for people who have a specific type of blood condition called thalassemia. Thalassemia means your body can't make enough healthy red blood cells, which carry oxygen around your body. Because of this, many people with severe thalassemia, especially those with what's called 'transfusion-dependent' alpha or beta thalassemia, need regular blood transfusions. These transfusions can make life difficult and have their own risks over time.
The main idea behind this study is to see if mitapivat can help people with thalassemia reduce how often they need these blood transfusions. Some participants will receive the actual medicine, while others will get a placebo, which looks like the medicine but contains no active ingredients. This helps researchers fairly compare the new drug's effects. Knowing if a medicine can lessen the need for transfusions is very important because it could greatly improve daily life for people with thalassemia and reduce the associated medical burdens.
This is a Phase 3 study, which means it's a large, in-depth trial involving many participants. Medicines reach this stage after showing encouraging results in earlier, smaller studies. The detailed description states that 171 people were given mitapivat and 87 were given the placebo. This setup allows the researchers to gather strong evidence about the medicine's effectiveness and safety, helping them decide if it could become a widely available treatment in the future. The ultimate aim is to find better ways to manage thalassemia and improve the health and well-being of those affected.
Punti chiave
- This study is testing a new medicine for severe thalassemia.
- It aims to reduce the need for blood transfusions.
- Participants will receive either the new medicine or a dummy treatment.
- It's a large study, meaning the medicine has shown promise in earlier tests.
- Careful monitoring of health and safety will be provided.
- La partecipazione è volontaria e puoi ritirarti in qualsiasi momento.
Chi può essere idoneo?
To join this study, you would need to be at least 18 years old and have a confirmed diagnosis of alpha or beta thalassemia based on genetic tests. A key requirement is that your thalassemia is considered 'transfusion-dependent'. This means you've needed between 6 and 20 units of red blood cells and haven't gone longer than six weeks without a transfusion in the six months before the study starts. If you're currently taking a medicine called hydroxyurea, your dose must have been stable for at least 16 weeks before you can join.
There are also some reasons why you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you've recently had other specific treatments like gene therapy or a bone marrow transplant. You also wouldn't be eligible if you have certain other serious health issues, like active heart or lung disease, or a recent history of certain cancers. The study also cannot include those who have recently used other specific thalassemia medications like luspatercept or other blood-stimulating agents.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Do you have a confirmed diagnosis of alpha or beta thalassemia?
- Do you need regular blood transfusions for your thalassemia (6-20 units in the last 6 months, and no longer than 6 weeks without a transfusion)?
- Non sei incinta o stai allattando?
- Have you spoken to your doctor about this study and understand the requirements?
Cosa comporta la partecipazione?
If you decide to take part in this study, you will be given either the study medicine, mitapivat, or a placebo (a dummy pill). You won't know which one you're receiving, and neither will your local study team, until the study is over. You'll have regular visits to the hospital or clinic where doctors will monitor your health, perform blood tests, and check how often you need blood transfusions. These visits are important to track the medicine's effects and ensure your safety. The study involves taking the medication for a set period, and there will be follow-up appointments even after you stop taking the study drug to see how you're doing. The total duration of your participation, including follow-up, will be explained in detail by the study team.
Rischi e benefici potenziali
Località (75)
- Phoenix Children's HospitalCodice postale verificatoPhoenix, Stati Uniti
- San Diego Hospital, UC San Diego HealthCodice postale verificatoLa Jolla, Stati Uniti
- Children's Hospital OaklandCodice postale verificatoOakland, Stati Uniti
- Stanford MedicineCodice postale verificatoPalo Alto, Stati Uniti
- Ospedale Pediatrico di BostonCodice postale verificatoBoston, Stati Uniti
- Ospedale Pediatrico del MichiganCodice postale verificatoDetroit, Stati Uniti
- Weill Cornell Medical CenterCodice postale verificatoNew York, Stati Uniti
- Duke University Medical CenterCodice postale verificatoDurham, Stati Uniti
- Penn Medicine - University of Pennsylvania Health SystemCodice postale verificatoPhiladelphia, Stati Uniti
- Seattle Cancer Care Alliance, University of WashingtonCodice postale verificatoSeattle, Stati Uniti
- Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USPCodice postale verificatoRibeirão Preto, Brazil
- GSH Banco de Sangue de São PauloCodice postale verificatoSão Paulo, Brazil
Domande comuni
What is thalassemia?
Thalassemia is a genetic blood disorder where your body doesn't produce enough healthy red blood cells, leading to anaemia and other health issues.
What does 'transfusion-dependent' mean?
It means you regularly need blood transfusions because your body can't make enough red blood cells on its own to stay healthy.
Che cos'è un placebo?
A placebo is a substance or treatment that looks exactly like the study medicine but doesn't contain any active ingredients. It's used for comparison.
Why can't I be pregnant or breastfeeding?
For your safety and the safety of your baby, pregnant or breastfeeding individuals are typically not included in drug trials because medicines can affect a developing baby or be passed through breast milk.
Will I feel better right away?
There's no guarantee the medicine will work, or how quickly. The study aims to see effects over time, and your health will be closely monitored.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.